ArticleRedox biology2026
Melatonin reprograms antioxidant defenses to suppress ferroptosis via Homer1a/mGluR1-Nrf2/xCT signaling after retinal ischemia-reperfusion.
Article in Redox biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melatonin (Mel) exerts antioxidant and anti-ferroptosis effects not only via the canonical receptors Mt1/Mt2 but also via metabotropic glutamate receptor 1 (mGluR1)/glutamate-mediated signaling. Nevertheless, the regulatory mechanism by which Mel modulates mGluR1/glutamate signaling in retinal ischemia-reperfusion (I/R) injury and its downstream effects on ferroptosis and oxidative stress remain poorly understood. Here, bulk RNA sequencing identified that the Mel receptors Mt1/Mt2 and ferroptosis/iron-redox regulators (Gpx4, Fth1, and xCT) were significantly downregulated after retinal I/R. Mel improved retinal structural and visual function, visual-guidance behavior, and electrophysiological responses following I/R while concurrently reducing ferroptotic and inflammatory injury markers. These benefits were largely abolished by Mel membrane receptor antagonists. Mechanistically, Mel upregulated Homer1a in vivo and in vitro in a receptor-dependent manner. Conditional deletion of Homer1a in transgenic mice, as well as Homer1a knockdown in retinal ganglion cells (RGCs), abolished the protective effects of Mel on visual function, along with its anti-ferroptotic and anti-inflammatory activities. Molecular docking and immunoprecipitation assays demonstrated that Mel restored the interaction between Homer1a and mGluR1 and activated the xCT/GSH/Gpx4 antioxidant axis. Pharmacologic inhibition of xCT with the buthionine sulfoximine (BSO) simulation pr genetic interference with xCT expression counteracted the protective effects of Mel. Mel also enhanced Nrf2-mediated transcriptional expression of cCT in a Homer1a/mGluR1-dependent manner. Collectively, our results define a Mel-Homer1a/mGluR1-Nrf2/xCT signaling cascade that promotes RGCs survival after I/R by suppressing ferroptosis/iron-redox reactions, thereby providing a potential translatable strategy for receptor-targeted intervention in I/R-related retinal damage.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.